Intranasal Drug Delivery Devices Global Market Report 2024

The intranasal drug delivery devices market size has grown strongly in recent years. It will grow from $55.27 billion in 2023 to $60.27 billion in 2024 at a compound annual growth rate (CAGR) of 9%. The growth observed in the historical period can be attributed to several factors, including an increase in chronic respiratory diseases, elevated patient preference and compliance, the convenience of self-administration, applications in pediatrics, market expansion in allergic rhinitis treatment, and a broader range of indications.

The intranasal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $84.51 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing geriatric population, a rise in global respiratory issues, expanding applications in neurological disorders, trends in personalized medicine, initiatives in preventive healthcare, and market penetration in emerging economies. Major trends expected in the forecast period include advances in formulation technologies, a heightened focus on pediatric and geriatric applications, an increase in self-administration devices, the emergence of nasal powder inhalers, and the incorporation of biologics and peptides.

The anticipated rise in the prevalence of chronic diseases is poised to drive the growth of the intranasal drug delivery devices market in the future. Chronic diseases, characterized by lasting for a year or more and requiring ongoing medical attention that limits daily activities, can be effectively managed using intranasal drug delivery devices. These devices offer a non-invasive and efficient means of administering medications, delivering them directly to the affected area. This method is both convenient and promotes rapid absorption. For instance, a report published by the National Institutes of Health (NIH) in September 2022 indicated that in the United States, the number of individuals aged 50 and older with at least one chronic illness is projected to increase by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, the number of people with multimorbidity is expected to rise by 91.16%, from 7.8304 million in 2020 to 14.968 million in 2050. Hence, the increasing prevalence of chronic diseases is a driving factor for the growth of the intranasal drug delivery devices market.

The growing demand for non-invasive drug delivery methods is also expected to contribute to the expansion of the intranasal drug delivery device market. Non-invasive drug delivery involves administering pharmaceutical substances into the body without the need for skin or mucous membrane penetration or incision. Intranasal drug delivery devices play a crucial role in facilitating this approach, making it easy and effective to administer drugs through the nose. Leveraging the nose's extensive blood vessel network and ensuring fast absorption, these devices enhance drug bioavailability, improve patient adherence, and eliminate the need for invasive procedures. For example, data from The Aesthetic Society in August 2023 highlighted a significant increase in nonsurgical procedures in the U.S., with body contouring, skin treatment, toxins, and micro-needling showing growth rates of 31%, 26%, 24%, and 23%, respectively, in 2022. As a result, the growing demand for non-invasive drug delivery methods is a key driver for the expansion of the intranasal drug delivery device market.

The anticipated risk of nasal irritation and other adverse effects is expected to act as a constraint on the growth of the intranasal drug delivery device market. Concerns regarding potential discomfort and safety issues may impede widespread acceptance and adoption of these devices for non-invasive drug delivery. As an example, data from the Centers for Disease Control and Prevention (CDC) in January 2022 revealed that 28.9 million adults in the United States, accounting for 11.6% of the adult population, had been diagnosed with sinusitis. Sinusitis leads to approximately 73 million restricted activity days annually. Consequently, the perceived risk of nasal irritation and other adverse effects may hinder the growth of the intranasal drug delivery device market.

Major pharmaceutical companies in the nasal drug delivery technology market are actively engaged in developing new and improved products to offer innovative drug administration methods and maintain their market position. For instance, in January 2023, AptarGroup, Inc., a US-based drug delivery and pharmaceutical company, introduced APF Futurity, the first recyclable, metal-free, multidose nasal spray for delivering nasal saline and similar over-the-counter (OTC) formulations. This product, made from polyolefin materials and devoid of metal components or recycling disruptors, reduces the need for separation in recycling streams and supports a higher grade of recycled materials. Notably, APF Futurity is a highly recyclable nasal spray pump that has obtained Class AA certification from cyclos-HTP for recycling streams in Europe.

In March 2022, Sandoz AG, a Switzerland-based biopharmaceutical company under the Novartis Group, acquired Coalesce Product Development Limited for an undisclosed amount. This strategic move aims to enhance Sandoz's capabilities in inhalation drug delivery, add a commercial-stage product to its portfolio, and expedite the development and commercialization of intranasal drug delivery devices. Coalesce Product Development Limited, based in the UK, specializes in drug delivery device development, including nasal drug delivery.

Major companies operating in the intranasal drug delivery devices market report are Johnson and Johnson Inc., Merck and Co.Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline PLC, 3M Company, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., AptarGroup Inc., West Pharmaceutical Services Inc., Teleflex Incorporated, Recipharm AB, Nemera Development S.A., Consort Medical plc., Vectura Group PLC, Douglas Pharmaceuticals Ltd., Avanir Pharmaceuticals, OptiNoset Inc., Flamel Technologies, Aegis Therapeutics LLC, Sonoma Pharmaceuticals, PendoPharm Inc., Kurve Technology Inc., Impel NeuroPharma, Impexium Medical Products, B.F. Ascher and Company Inc., ENT Technologies Pty. Ltd., Neurelis Inc., Generex Biotechnology Corporation.

North America was the largest region in the intranasal drug delivery devices market in 2023. The regions covered in the intranasal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intranasal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Intranasal drug delivery devices are medical instruments designed to administer medications into the nasal cavity. These devices are specifically created to deliver medications directly to the highly vascularized nasal mucosa, which boasts a substantial surface area, facilitating rapid absorption of the drug into the bloodstream. Intranasal drug delivery devices are capable of delivering drugs or therapeutic substances in various forms, including sprays, powders, or liquid solutions, directly into the nasal cavity.

The primary products within the realm of intranasal drug delivery devices include powder delivery devices, liquid delivery devices, pressurized metered-dose inhalers, and other related devices. Powder delivery devices, a subtype of medical or pharmaceutical devices, are designed for administering medications in unit-dose or multi-dose forms and find applications in various medical conditions such as chronic obstructive pulmonary disease (COPD), rhinitis, cystic fibrosis, nasal congestion, asthma, among others. The end users of these devices include hospitals, clinics, homecare, and other healthcare settings.

The intranasal drug delivery devices market research report is one of a series of new reports that provides intranasal drug delivery devices market statistics, including intranasal drug delivery devices industry global market size, regional shares, competitors with a intranasal drug delivery devices market share, detailed intranasal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the intranasal drug delivery devices industry. This intranasal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intranasal drug delivery devices market consists of sales of nasal sprays, nasal powder devices, nasal antipsychotic medications, nasal epinephrine devices, nasal drops, and nasal inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.